Articles producció científica> Bioquímica i Biotecnologia

Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide. [Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein].

  • Datos identificativos

    Identificador: imarina:5129102
    Autores:
    Folch, JEttcheto, MPetrov, DAbad, SPedros, IMarin, MOlloquequi, JCamins, A
    Resumen:
    Alzheimer disease (AD) is a major neurodegenerative disorder which eventually results in total intellectual disability. The high global prevalence and the socioeconomic burden associated with the disease pose major challenges for public health in the 21st century. In this review we focus on both existing treatments and the therapies being developed, which principally target the β-amyloid protein. DISCUSSION: The amyloidogenic hypothesis proposes that β-amyloid plays a key role in AD. Several pharmacological approaches aim to reduce the formation of β-amyloid peptides by inhibiting the β-secretase and γ-secretase enzymes. In addition, both passive and active immunotherapies have been developed for the purpose of inhibiting β-amyloid peptide aggregation. CONCLUSIONS: Progress in identifying the molecular basis of AD may provide better models for understanding the causes of this neurodegenerative disease. The lack of efficacy of solanezumab (a humanised monoclonal antibody that promotes β-amyloid clearance in the brain), demonstrated by 2 recent Phase III clinical trials in patients with mild AD, suggests that the amyloidogenic hypothesis needs to be revised.
  • Otros:

    Autor según el artículo: Folch, J; Ettcheto, M; Petrov, D; Abad, S; Pedros, I; Marin, M; Olloquequi, J; Camins, A
    Departamento: Bioquímica i Biotecnologia
    Autor/es de la URV: Folch Lopez, Jaume
    Palabras clave: Solanezumab Humans Hipótesis amiloidea Gamma-secretase Gamma-secretasa Beta-secretase Beta-secretasa Beta-amyloid Beta-amiloide App protein, human Antibodies, monoclonal, humanized Amyloid precursor protein secretases Amyloid hypotheses Amyloid beta-protein precursor Amyloid beta-peptides Alzheimer disease Alzheimer gamma-secretase gamma-secretasa beta-secretase beta-secretasa beta-amyloid beta-amiloide amyloid hypotheses alzheimer disease alzheimer
    Resumen: Alzheimer disease (AD) is a major neurodegenerative disorder which eventually results in total intellectual disability. The high global prevalence and the socioeconomic burden associated with the disease pose major challenges for public health in the 21st century. In this review we focus on both existing treatments and the therapies being developed, which principally target the β-amyloid protein. DISCUSSION: The amyloidogenic hypothesis proposes that β-amyloid plays a key role in AD. Several pharmacological approaches aim to reduce the formation of β-amyloid peptides by inhibiting the β-secretase and γ-secretase enzymes. In addition, both passive and active immunotherapies have been developed for the purpose of inhibiting β-amyloid peptide aggregation. CONCLUSIONS: Progress in identifying the molecular basis of AD may provide better models for understanding the causes of this neurodegenerative disease. The lack of efficacy of solanezumab (a humanised monoclonal antibody that promotes β-amyloid clearance in the brain), demonstrated by 2 recent Phase III clinical trials in patients with mild AD, suggests that the amyloidogenic hypothesis needs to be revised.
    Áreas temáticas: Psicología Neurology (clinical) Medicine (miscellaneous) Medicina ii Medicina i General medicine Clinical neurology
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 15781968
    Direcció de correo del autor: jaume.folch@urv.cat
    Identificador del autor: 0000-0002-5051-8858
    Fecha de alta del registro: 2024-10-19
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://www.sciencedirect.com/science/article/pii/S021348531500064X?via%3Dihub
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: Neurologia. 33 (1): 47-58
    Referencia de l'ítem segons les normes APA: Folch, J; Ettcheto, M; Petrov, D; Abad, S; Pedros, I; Marin, M; Olloquequi, J; Camins, A (2018). Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide. [Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein].. Neurologia, 33(1), 47-58. DOI: 10.1016/j.nrl.2015.03.012
    DOI del artículo: 10.1016/j.nrl.2015.03.012
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2018
    Tipo de publicación: Journal Publications
  • Palabras clave:

    Clinical Neurology,Medicine (Miscellaneous),Neurology (Clinical)
    Solanezumab
    Humans
    Hipótesis amiloidea
    Gamma-secretase
    Gamma-secretasa
    Beta-secretase
    Beta-secretasa
    Beta-amyloid
    Beta-amiloide
    App protein, human
    Antibodies, monoclonal, humanized
    Amyloid precursor protein secretases
    Amyloid hypotheses
    Amyloid beta-protein precursor
    Amyloid beta-peptides
    Alzheimer disease
    Alzheimer
    gamma-secretase
    gamma-secretasa
    beta-secretase
    beta-secretasa
    beta-amyloid
    beta-amiloide
    amyloid hypotheses
    alzheimer disease
    alzheimer
    Psicología
    Neurology (clinical)
    Medicine (miscellaneous)
    Medicina ii
    Medicina i
    General medicine
    Clinical neurology
  • Documentos:

  • Cerca a google

    Search to google scholar